ECCO 2026

Precision medicine - from a static to a dynamic system

Early treatment concepts with infliximab

IL-23 - is this the good-bye from systemic therapy?

IL-23: from real-world to special patient population

Deeper endpoints in clincial trials and RW

Update on upadacitinib vs. risankizumab after anti-TNF…

Fistulizing disease - what can we do better?

Diet as prevention and early intervention in Crohn’s…

Exciting new data on surgery - for all patient groups?

Evolving landscape of anti-fibrotic therapy in IBD

What is the best treatment approach in IBD?

Molecular medicine driving treatment decisioning!?

Molecular signature–driven therapy

Stop of thiopurines in patients on subcutaneous…

Should we stop thiopurines in IBD patients who are…

Top-down- versus Step-up-Therapie beim Morbus Crohn

Was ist der beste Therapieansatz bei CED?

Molekulare Medizin als Wegweiser für…

JAK–STAT inhibition as a therapeutic approach for…

Long-term risankizumab persistence

Top-down vs. step-up therapy in CD

Early use of infliximab positively influences longterm…

Do we need immediate postoperative prophylaxis?

Should we prevent or treat post-operative recurrence in…

LIR!C — suivi 10 ans: bénéfice de la chirurgie?

Früher Einsatz von Infliximab verbessert das…

JAK-STAT Hemmung zur Fistel-Therapie

Top-down vs. Step-up Therapie beim Morbus Crohn

Is onmiddellijke postoperatieve preventie nodig?

Treat-2-target strategy in UC

Steroid sparing effect of filgotinib in UC

ASUC: smarter use of third-line rescue therapy

Pouch surgery: only for expert centers

Combination therapy with tofacitinib and…

Effetto steroid-sparing di filgotinib nella colite…

Pouchchirurgie: enkel voor expertisecentra

Tofacitinib-Steroid-Kombination bei ASUC

ASUC: Derde‑lijn­therapie slimmer inzetten

Resultados a largo plazo tras apendicectomía en colitis…

The risk of colorectal neoplasia in IBD

Long-term outcomes of IL‑23 inhibitors

Langetermijn data van IL‑23 inhibitoren

Risque de cancer colorectal dans les MICI

Ustekinumab is effective and safe for paediatric…

UPA vs RISA in Crohn’s disease – a decision dilemma

Histo-endoscopic outcomes of upadacitinib in CD

Guselkumab – does it treat only the gut?

Guselkumab may improve and prevent extraintestinal…

Nicht nur im Darm – Wirksamkeit von Guselkumab bei…

UPA vs RISA w chorobie Leśniowskiego-Crohna – sztuka…

Guselkumab può migliorare e prevenire le manifestazioni…

Το ustekinumab είναι αποτελεσματικό και ασφαλές σε…

Short term transmural healing detected by US in CD…

Etrasimod in the milder moderate UC patients

Long-term efficacy and safety of risankizumab in UC

Vedolizumab combined with upadacitinib vs Vedolizumab…

Early symptomatic response with IL-23 blockers

Mirikizumab is able to induce disease clearence in…

Does colectomy reduce the risk of death in UC?

Early and durable response with guselkumab

Etrasimod efficacy in mildly-to-moderately active UC…

Efficacy and safety of vedolizumab + upadacitinib as…

Short-term effectiveness and safety of Mirikizumab in…

Efficacia di Etrasimod in pazienti affetti da colite…

Efficacia e sicurezza a lungo termine di risankizumab…

Efficacia e sicurezza di vedolizumab + upadacitinib…

Efectividad y seguridad a corto plazo de Mirikizumab en…

Vedolizumab combinado con upadacitinib vs Vedolizumab…

Est-ce que la colectomie réduit le risque de décès dans…

Frühes symptomatisches Ansprechen unter IL-23-Blockade

Ontunisertib - ALK5 blockage in fistulizing CD

B-cells step into the spotlight

AGMB-129, Ontunisertib, new MoA in patients with…

Cytotoxic CD4+ accumulate in the UC but not CD mucosa…

Appendectomy - a new therapeutic option in UC

The STENOVA Trial. Ontunisertib shows promising results…

Impact of icotrokinra on biomarkers in UC

L’accumulo di cellule citotossiche CD4+ caratterizza la…

Apendektomie - eine neue Therapieoption bei Colitis…

Impact de l’icotrokinra sur les biomarqueurs dans la…

Ikotrokinkra a stan zapalny w colitis ulcerosa

AGMB-129, Ontunisertib, nueva terapia para pacientes…

Ontunisertib – ALK5-Blockade bei fistulierendem Morbus…

Η μελέτη STENOVA: Το ontunisertib δείχνει υποσχόμενα…

IBDMED going global!

ADHD and autism in IBD – the same or different story?

IBDMED מעבר לאזור הים התיכון